LGC Group, a global leader in life sciences, today officially opened its new Organic Chemistry Synthesis Centre of Excellence in Vaughan, Ontario, following a CAD $100 million investment. The 203,000-square-foot facility is one of the largest of its kind in the world and significantly expands Toronto Research Chemicals’ (TRC) capacity to serve pharmaceutical, biotechnology, and life sciences customers worldwide.
Founded more than 40 years ago and acquired by LGC in 2019, TRC is internationally recognised for its expertise in synthesising complex organic molecules, many of which are only available from TRC. These compounds underpin global drug discovery pipelines, diagnostic development, forensic testing, food and environmental safety, and industrial innovation, giving customers reliable access to critical building blocks for science.
“This $100 million investment is about building capacity at scale, giving our customers faster, more reliable access to the essential tools that enable breakthroughs,” said Joydeep Goswami, CEO of LGC Group. “From Vaughan, our scientists will help tackle challenges like precision medicine, PFAS detection, and sustainable chemistry, while supplying the world with solutions that protect health, food, and the environment.”
Products manufactured at the new facility will be shipped to more than 170 countries, enabling research in areas such as cancer, infectious disease, mental health, and environmental safety. For customers, the expansion means greater reliability, scale, and speed of delivery at a time when the demand for high-quality, specialised research chemicals is growing rapidly.
“TRC’s science may start in our labs, but its impact is felt worldwide – in hospitals, communities, and industries that depend on reliable answers,” said Bruno Rossi, EVP and General Manager, LGC Standards. “With this new facility, we’re building on 40 years of expertise to deliver faster, broader, and more sustainable innovation for scientists everywhere.”
